American ginseng does not improve fatigue in multiple sclerosis: a single center randomized double-blind placebo-controlled crossover pilot study

Mult Scler. 2011 Dec;17(12):1523-6. doi: 10.1177/1352458511412062. Epub 2011 Jul 29.


This study examined the safety and efficacy of an escalating dose (100 mg, 200 mg, 400 mg/day) of American ginseng over 6 weeks in a single-center, randomized, double-blind, placebo-controlled, crossover trial with 56 subjects with multiple sclerosis and fatigue. There were no serious adverse events but fatigue on ginseng, as assessed by the Fatigue Severity Scale, was not significantly different from fatigue on placebo.

Publication types

  • Controlled Clinical Trial
  • Randomized Controlled Trial
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, Non-P.H.S.

MeSH terms

  • Cross-Over Studies
  • Double-Blind Method
  • Fatigue / complications
  • Fatigue / drug therapy*
  • Humans
  • Multiple Sclerosis / complications*
  • Multiple Sclerosis / physiopathology
  • Panax*
  • Phytotherapy*
  • Pilot Projects*
  • Plant Extracts / therapeutic use
  • Treatment Outcome
  • United States


  • Plant Extracts